Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer

被引：0
作者：
Hong Jin
Yundan Liang
Xunli Wang
Jingqiang Zhu
Ruifen Sun
Peng Chen
Xinwen Nie
Linbo Gao
Lin Zhang
机构：
[1] Sichuan University,Department of Immunology, West China School of Preclinical and Forensic Medicine
[2] Hospital of Yunnan University of Nationalities,Department of Thyroid and Breast Surgery
[3] West China Hospital of Sichuan University,Laboratory of Molecular and Translational Medicine, West China Institute of Women and Children’s Health; West China Second University Hospital
[4] Sichuan University,undefined
[5] Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education,undefined
来源：
Medical Oncology | 2014年 / 31卷
关键词：
Let-7; Polymorphism; Papillary thyroid cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
KRAS mutation is frequently detected in a series of cancers, including papillary thyroid cancer (PTC). Recently, a genetic variant of rs712 in the 3′ untranslated region of the KRAS gene has been reported to be functional in the regulation of KRAS by disrupting complementary site of let-7 and miR-181. We aimed to investigate whether the polymorphism is a risk factor for PTC. We conducted an association study, including 252 PTC patients and 290 healthy controls. The KRAS rs712 polymorphism was genotyped by polymerase chain reaction–restriction fragment length polymorphism. Although no significant difference of the KRAS rs712 distribution was observed between cases and controls in overall analysis, stratification analysis showed that patients carrying the KRAS rs712TT genotype were less likely to develop stages T3 and T4 under a recessive genetic model (OR 0.26, 95 % CI 0.08–0.82). These results supported the role of the KRAS rs712 polymorphism as a potential genetic biomarker for the extension of PTC. Further population-based association studies are of great value to confirm the results in diverse ethnicities.
引用
收藏
相关论文
共 131 条
[11]  
Tumanov KA(2014)The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations J Clin Endocrinol Metab 99 E276-E285
[12]  
Jazdzewski K(2013)Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis Clin Chem Lab Med 51 1673-1680
[13]  
Murray EL(2014)A subset of papillary thyroid carcinomas contain KRAS mutant subpopulations at levels above normal thyroid Mol Carcinog 53 159-167
[14]  
Franssila K(2014)Extensive sequence variation in the 3′ untranslated region of the KRAS gene in lung and ovarian cancer cases Cell Cycle 13 1030-1040
[15]  
Jarzab B(2012)MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2 J Cancer Res Clin Oncol 138 573-584
[16]  
Schoenberg DR(2007)Impaired microRNA processing enhances cellular transformation and tumorigenesis Nat Genet 39 673-677
[17]  
Gao L(2012)Effects of KRAS mutation and polymorphism on the risk and prognosis of oral squamous cell carcinoma Head Neck 34 663-666
[18]  
Zhu X(2013)A let-7 binding site polymorphism rs712 in the KRAS 3′ UTR is associated with an increased risk of gastric cancer Tumour Biol 34 3159-3163
[19]  
Li Z(2014)A let-7 KRAS rs712 polymorphism increases colorectal cancer risk Tumour Biol 35 831-835
[20]  
Li L(2014)Lack of association between let-7 binding site polymorphism rs712 and risk of nasopharyngeal carcinoma Fam Cancer 13 93-97
12345678910